About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Antibody Drug Conjugates (ADCs) Market Global Market Analysis and Industry Forecast: 2022-2030

REPORT OVERVIEW:

Antibody Drug Conjugates or (ADCs) is a novel cancer treatment that combines the targeting ability of antibodies with the killing power of chemotherapy. It is mainly composed of a monoclonal antibody (mAb) linked to a highly cytotoxic agent or payload via a synthetic linker.

ADCs function by targeting and attaching to certain tumor cell surface proteins known as antigens. Upon internalization, the attached cytotoxic payload is released into the targeted cell, causing microtubule disruption or DNA damage, resulting in apoptosis or cell death.

ADCs have become an innovative solution to treat various hematological and solid tumor indications due to the benefits associated with them such as selectively killing cancerous cells while sparing healthy cells, easy administration, high efficacy, and cost-effective option as compared to other available immunotherapy products.

Since the first ADC Mylotarg was approved in 2000, so far 13 ADC products have received market approval, including Adcetris, Kadcyla, Enhertu, and, most recently approved, Elahere (Mirvetuximab Soravtansine).

Currently, 314 ADCs are being evaluated in clinical trials, with 15 late-stage candidates expected to receive market approval during the forecast period.

According to Biotech Forecasts, the Global Antibody Drug Conjugates (ADCs) Market was valued at USD 5,270.44 Million in 2021, and it is estimated to reach USD 33,393.98 Million by 2030, registering a CAGR of 18.92% from 2022 to 2030.

Factors that drive the market growth involve, (1) Surging Investment Pertaining to ADCs: Venture capital landscape of ADCs is soaring with high investments. For instance, in May 2022 Tubulis raised  €60 Million in series B, in December 2021 Emergence Therapeutics raised €87M in Series A. Furthermore, in February 2022, Synaffix signed a collaboration deal value of up to  USD 586 million with MacroGenics to develop three next generation ADCs.

(2) The rise in the prevalence of cancer: Increasing cancer patient population is the major factor driving the market growth. According to WHO statistics, cancer was responsible for approximately 10 million deaths worldwide in 2020, and it is anticipated to reach 17 million deaths by 2030.

Other factors that fuel the market growth involve, the surging number of approved products, and rising demand for antibody based therapies. However, the high costs associated with the process, and potential side effects might hamper the market growth.

The report also presents a detailed quantitative analysis of the current market trends and future estimations from 2022 to 2030. The forecasts cover 7 Antigen Types, 8 Products, 4 Applications, and 4 Regions.

The report comes with an associated file covering quantitative data from all numeric forecasts presented in the report, as well as a clinical trial data file.

TOPICS COVERED:

The report covers the following topics:

 

  • Market Drivers, Restraints, and Opportunities
  • Porter’s Five Forces Analysis
  • Key Developments in ADCs Market
  • Market Analysis by Antigen Type, Product, Application, and Region
  • Clinical Trials Analysis from 2000 to Q3-2022
  • 13 Approved Product Profiles, Financial Overview, and Key Developments
  • 20 Company Profiles, ADCs Pipeline, Financial overview, and Key Strategies
  • Market analysis and forecast from 2022 to 2030

 

FORECAST SEGMENTATION:

Market forecasts are provided for each of the following submarkets and their categories:

1- By Antigen Type

 

  • HER2
  • CD30
  • Nectin-4
  • TROP-2
  • CD22
  • BCMA
  • Others

 

2- By Product

  • Kadcyla
  • Adcetris
  • Enhertu
  • Padcev
  • Trodelvy
  • Polivy
  • Besponsa
  • Others

 

3- By Application

 

  • Breast Cancer
  • Blood Cancer
  • Urothelial Cancer
  • Others

 

4- By Region

 

  • North America: USA, Canada,  Mexico
  • Europe: The U.K., Germany, France, Switzerland, Italy, Spain, Rest of Europe
  • Asia-Pacific: China, Japan, South Korea, India, Rest of Asia-Pacific
  • LAMEA: Brazil, South Africa, Rest of LAMEA
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.